To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Europe | European ＆ international partnerships | Immune system
Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK
ABIRISK Project aims to provide an integrated approach to anti-drug (AD) immunization, bringing together, a large network of clinicians from various specialties with broad experience in the care of patients treated with various type of biopharmaceuticals products and developing AD antibodies, biologists familiar with the immune monitoring of patients, scientists specialized in the mechanisms of immunogenicity, methodologists and biostatisticians.
A growing number of drugs are based on biological molecules such as proteins and monoclonal antibodies. These new drugs have led to the development of new and more effective treatments for a number of serious conditions. However, these drugs sometimes trigger a reaction from the patient's immune system, which can decrease the effectiveness of the drug or cause serious side effects. The goal of the IMI-funded ABIRISK project is to shed new light on the factors behind this immune response. The project, which represents the first extensive and coordinated effort to address this problem, was officially launched on March 1, 2012. ABIRISK will contribute to the creation of new, safer biopharmaceuticals and will also generate tools to determine how individual patients are likely to respond, both in clinical trials and after they are on the market.
Joliot Institute Contact: Bernard Maillère (firstname.lastname@example.org)
ABOUT IMI - INNOVATIVE MEDICINES INITIATIVE
IMI is the world's largest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
The objective of IMI, particularly in its second phase (IMI2, 2014-2020), is to develop new generation vaccines, drugs and treatments, such as new antibiotics.
For more information: https://www.imi.europa.eu/
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.